Effect of PTH analogue-treatment on prevention of secondary new vertebral compression fracture.

Comparison of Efficacy of PTH analogue and other therapy on the prevention of subsequent vertebral compression fracture after percutaneous vertebroplasty in patients with high risk for subsequent vertebral compression fracture: prospective comparative analysis between PTH analogue-treated group and other therapy (bisphosphonate, SERM)-treated group

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0003918

Enrollment

Registered

2019-05-15

Start date

2019-05-23

Completion date

Unknown

Last updated

2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : PTH analogue injection (Terivone 56.5ug) Risendronate (Actonel EC TAB 35mg) SERM (EVISTA tab 60mg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) BMD: T score > -3.7 (2) PVP-treated patient for OVCF (3) Patients who meet all of the above criteria will be defined as the high risk group of secondary new compressionl fracture.

Exclusion criteria

Exclusion criteria: (1) Pathologic fracture: metastatic vertebral fracture, benign or malignant tumor of vertebral body (ex: multiple myeloma) (2) Spinal infection (3) Previous spinal surgery (4) Systemic disease result in osteoporosis (ex: Vitamin D deficiency, Diabetes Mellitus, previous paresis) (5) Patients with multiple compression fracture

Design outcomes

Primary

Measure	Time frame
subsequent vertebral compression fracture after percutaneous vertebroplasty-treated osteoporotic vertebral compression fracture	—

Secondary

Measure	Time frame
Visual Aanlogue Scale score after percutaneous vertebroplasty	—

Countries

Korea, Republic of

Contacts

Public ContactHong-Jae Lee

The Catholic University of Korea, Daejeon St. Mary's Hospital

lhjoc9506@naver.com+82-42-220-9251

Outcome results